KRAS

Assessing the heterogeneity0:02:42

Assessing the heterogeneity of KRAS-mutant pancreatic adenocarcinomas

Improving outcomes in0:00:41

Improving outcomes in KRAS-mutant pancreatic cancer

Overcoming the Undruggable1:01:44

Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras

Unmet needs in0:00:41

Unmet needs in KRAS-driven non-small cell lung cancer

Drugging the Elusive0:04:30

Drugging the Elusive KRAS

A New Era0:04:09

A New Era in Targeting KRAS

An Overview of0:04:10

An Overview of KRAS Tumor Biology

How do doctors0:02:31

How do doctors treat lung cancer with KRAS mutations?

Molecular determinants of0:01:59

Molecular determinants of KRAS G12C inhibitor efficacy in advanced NSCLC

KRAS G12C Inhibitors0:03:56

KRAS G12C Inhibitors Versus Chemotherapy in Second Line - Targeted Therapies in Lung Cancer 2023

KRAS Mutation Subtypes0:05:57

KRAS Mutation Subtypes in Advanced NSCLC

History of KRAS0:04:41

History of KRAS Testing in Advanced NSCLC

LY3537982: a novel0:01:19

LY3537982: a novel KRAS G12C inhibitor in solid tumors

“Is KRAS Druggable?”0:03:51

“Is KRAS Druggable?” Experts in Pancreatic Cancer and KRAS Discuss Tough Questions

Targeted Therapy for0:07:23

Targeted Therapy for KRAS-Mutant NSCLC

KRAS una GTPasa0:00:39

KRAS una GTPasa y miembro de la familia de las proteínas RAS

VDRHSE Talks: KRAS0:01:01

VDRHSE Talks: KRAS Protein

Learning More about0:02:17

Learning More about KRAS Lung Cancer

Inhibidores de la0:01:14

Inhibidores de la proteina KRAS

KRAS - Dr.ª0:01:16

KRAS - Dr.ª Daniela Madama

KRAS Driven Cancers0:00:41

KRAS Driven Cancers (KRAS episode 2)

Análise molecular e0:13:48

Análise molecular e mutação KRAS em CPNPC - Dr. Alessandro Leal - Precision Oncology Review 2020

Treatment Options for0:05:33

Treatment Options for KRAS-Mutant Unresectable mCRC

Mechanisms of acquired0:04:29

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Назад